BCRX - BioCryst Pharmaceuticals Reports Q1 Loss Tops Revenue Estimates | Benzinga
BioCryst Pharmaceuticals (NASDAQ: BCRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 26.09%. A quarter ago, it was expected that this drugmaker would post a loss of $0.24 per share when it actually produced a loss of $0.28, delivering a surprise of -16.67%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
BioCryst, which belongs to the Zacks Medical - Drugs industry, posted revenues of $92.76 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 8.37%. This compares to year-ago revenues of $68.78 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
BioCryst shares ...